Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Merck Sharp & Dohme LLC
Gilberto de Castro; Iveta Kudaba; Yi-Long Wu; Gilberto Lopes; Dariusz M Kowalski; Hande Z Turna; Christian Caglevic; Li Zhang; Boguslawa Karaszewska; Konstantin K Laktionov; Vichien Srimuninnimit; Igor Bondarenko; Kaoru Kubota; Rinee Mukherjee; Jianxin Lin; Fabricio Souza; Tony S K Mok; Byoung Chul Cho